$Conduit Pharmaceuticals (CDT.US)$ On Thursday, Conduit Phar...
$Conduit Pharmaceuticals (CDT.US)$ On Thursday, Conduit Pharmaceuticals Inc. (NASDAQ:CDT) entered into an agreement with AstraZeneca Plc (NASDAQ:AZN) to exclusively license rights to develop AZD1656 and AZD5658, both HK-4 glucokinase activators and AZD5904, a myeloperoxidase inhibitor (MPO
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment